BR0010711A - Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes - Google Patents

Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes

Info

Publication number
BR0010711A
BR0010711A BR0010711-5A BR0010711A BR0010711A BR 0010711 A BR0010711 A BR 0010711A BR 0010711 A BR0010711 A BR 0010711A BR 0010711 A BR0010711 A BR 0010711A
Authority
BR
Brazil
Prior art keywords
immune responses
soluble
stimulatory molecules
enhance immune
molecules
Prior art date
Application number
BR0010711-5A
Other languages
English (en)
Inventor
Knut Sturmhoefel
Stanley F Wolf
Margot O'toole
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of BR0010711A publication Critical patent/BR0010711A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Patente de Invenção: "USO DE MOLéCULAS CO-ESTIMULATóRIAS SOLúVEIS PARA INTENSIFICAR RESPOSTAS IMUNES". São proporcionados métodos de intensificação de respostas imunes nos quais formas solúveis de moléculas co-estimulatórias, por exemplo, moléculas B7, são administradas a fim de aumentar as respostas imunes a antígenos, por exemplo, a células tumorígenas e agentes infecciosos. Os métodos em questão são úteis para a imunização profilática e terapêutica de indivíduos.
BR0010711-5A 1999-05-06 2000-05-05 Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes BR0010711A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13294499P 1999-05-06 1999-05-06
PCT/US2000/012435 WO2000067788A2 (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses

Publications (1)

Publication Number Publication Date
BR0010711A true BR0010711A (pt) 2002-02-13

Family

ID=22456295

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010711-5A BR0010711A (pt) 1999-05-06 2000-05-05 Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes

Country Status (15)

Country Link
EP (1) EP1181053A2 (pt)
JP (1) JP2002544170A (pt)
KR (1) KR20020001865A (pt)
CN (1) CN1377279A (pt)
AU (1) AU4825700A (pt)
BR (1) BR0010711A (pt)
CA (1) CA2373256A1 (pt)
CZ (1) CZ20013964A3 (pt)
HK (1) HK1041810A1 (pt)
HU (1) HUP0201222A3 (pt)
IL (1) IL146106A0 (pt)
NO (1) NO20015396L (pt)
PL (1) PL360915A1 (pt)
WO (1) WO2000067788A2 (pt)
ZA (1) ZA200109376B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
EP1910387B1 (en) * 2005-06-30 2016-11-16 Eisai R&D Management Co., Ltd. Compounds for preparing immunological adjuvant
EP1973573B1 (en) 2005-12-08 2013-05-22 University of Louisville Research Foundation, Inc. Methods and compositions for expanding t regulatory cells
JP5564181B2 (ja) 2005-12-08 2014-07-30 シルワン，ハヴァル 免疫刺激組成物および方法
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
WO2013019669A2 (en) * 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
JP2015513915A (ja) * 2012-04-02 2015-05-18 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティＡｒｉｚｏｎａ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｆｏｒ Ａｎｄ Ｏｎ Ｂｅｈａｌｆ Ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞性免疫応答の誘導のための組換え細菌
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP3065771B1 (en) 2013-11-04 2019-03-20 UTI Limited Partnership Methods and compositions for sustained immunotherapy
KR20180011135A (ko) 2015-05-06 2018-01-31 유티아이 리미티드 파트너쉽 지속 치료를 위한 나노입자 조성물
CN110743006B (zh) * 2019-11-22 2020-08-25 北京启辰生生物科技有限公司 用于协同解除免疫细胞衰竭的组合物及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006605A2 (en) * 1998-07-28 2000-02-10 Micromet Ag Heterominibodies

Also Published As

Publication number Publication date
HUP0201222A2 (en) 2002-08-28
ZA200109376B (en) 2003-03-13
WO2000067788A3 (en) 2001-04-05
HUP0201222A3 (en) 2004-07-28
HK1041810A1 (zh) 2002-07-26
KR20020001865A (ko) 2002-01-09
IL146106A0 (en) 2002-07-25
PL360915A1 (en) 2004-09-20
NO20015396L (no) 2002-01-02
EP1181053A2 (en) 2002-02-27
CN1377279A (zh) 2002-10-30
WO2000067788A2 (en) 2000-11-16
AU4825700A (en) 2000-11-21
CZ20013964A3 (cs) 2002-06-12
CA2373256A1 (en) 2000-11-16
JP2002544170A (ja) 2002-12-24
NO20015396D0 (no) 2001-11-05

Similar Documents

Publication Publication Date Title
BR0010711A (pt) Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
AU3847801A (en) Proteosome influenza vaccine
BR9814487A (pt) "vacina"
WO1999010375A3 (en) Vaccine against hpv
BRPI0010612B8 (pt) vacinas
Lingnau et al. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
BR0311995A (pt) Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
EP1568373A3 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
WO1999050303A3 (en) Immune response modulator alpha-2 macroglobulin complex
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
ATE557099T1 (de) Hpv cd8+ t-zell-epitope
DE69720065T2 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
JP2004503217A5 (pt)
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos
WO2000012122A3 (de) Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
MY127452A (en) Vaccines.
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
WO2002032455A3 (en) Vaccine
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
JP2004514412A5 (pt)

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]